Sistema de Salut de Catalunya
Institut Català de la Salut
[Majem M] Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, c/Sant Antoni Maria Claret 167, 08025 Barcelona, Spain. Spanish Group for Cancer Immuno-Biotherapy, GÉTICA, Madrid, Spain. [García-Martínez E] Department of Medical Oncology and Hematology, Hospital Universitario Morales Meseguer, Murcia, Spain. Spanish Group for Cancer Immuno-Biotherapy, GÉTICA, Madrid, Spain. [Martinez M] Department of Medical Oncology, Hospital del Mar, Barcelona, Spain. [Muñoz-Couselo E] Servei de Medicina Oncològica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Melanoma and Other Skin Tumors Unit, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Rodriguez-Abreu D] Department of Medical Oncology, C.H.U. Insular-Materno Infantil de Gran Canaria, Las Palmas, Spain. Spanish Group for Cancer Immuno-Biotherapy, GÉTICA, Madrid, Spain. [Alvarez R] Department of Medical Oncology, Hospital Virgen de la Salud, Toledo, Spain
Vall d'Hebron Barcelona Hospital Campus
2021-09-15T07:39:25Z
2021-09-15T07:39:25Z
2020-02
Immunotherapy; Toxicity; irAEs
Inmunoterapia; Toxicidad; irAEs
Immunoteràpia; Toxicitat; irAEs
The use of immune checkpoint inhibitors has emerged as an effective treatment option for patients with several tumor types. By increasing the activity of the immune system, they can induce inflammatory side effects, which are often termed immune-related adverse events. These are pathophysiologically unique toxicities, compared with those from other anticancer therapies. In addition, the spectrum of the target organs is very broad. Immune-inflammatory adverse events can be life threatening. Prompt diagnosis and pharmacological intervention are instrumental to avoid progression to severe manifestations. Consequently, clinicians require new skills to successfully diagnose and manage these events. These SEOM guidelines have been developed with the consensus of ten medical oncologists. Relevant studies published in peer-review journals were used for the guideline elaboration. The Infectious Diseases Society of America grading system was used to assign levels of evidence and grades of recommendation.
Article
Published version
English
Immunoteràpia - Efectes secundaris; Càncer - Tractament; Protocols clínics; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy; Other subheadings::Other subheadings::Other subheadings::/adverse effects; DISEASES::Neoplasms; HEALTH CARE::Health Services Administration::Quality of Health Care::Quality Assurance, Health Care::Guidelines as Topic::Practice Guidelines as Topic; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapia biológica::inmunomodulación::inmunoterapia; Otros calificadores::Otros calificadores::Otros calificadores::/efectos adversos; ENFERMEDADES::neoplasias; ATENCIÓN DE SALUD::administración de los servicios de salud::calidad de la atención sanitaria::garantía de calidad de la atención sanitaria::directrices como asunto::guías de práctica clínica como asunto
Springer
Clinical and Translational Oncology;22
https://doi.org/10.1007/s12094-019-02273-x
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
Articles científics - HVH [3439]
